Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price

Orchard Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20222021202020192018 2017 - 2016
Market Capitalization
757471664221,1431,307
Upgrade
Market Cap Growth
--71.63%-60.77%-63.04%-12.59%-
Upgrade
Enterprise Value
679-395288863971
Upgrade
PE Ratio
-2.41-0.31-1.15-2.78-6.99-5.67
Upgrade
PS Ratio
34.652.0898.90162.73454.66629.62
Upgrade
PB Ratio
9.430.480.792.373.824.20
Upgrade
P/FCF Ratio
-2.03-0.63-1.30-3.08-6.70-12.87
Upgrade
P/OCF Ratio
-1.88-0.62-1.32-3.34-6.88-13.40
Upgrade
EV/Sales Ratio
31.10-1.713.01111.17343.60467.84
Upgrade
EV/EBITDA Ratio
-1.470.26-0.04-1.94-5.32-4.25
Upgrade
EV/EBIT Ratio
-1.420.26-0.04-1.92-5.26-4.23
Upgrade
EV/FCF Ratio
-1.130.52-0.04-2.10-5.06-9.56
Upgrade
Debt / Equity Ratio
0.600.590.280.330.15-
Upgrade
Debt / EBITDA Ratio
-0.72-0.39-0.43-0.39-0.28-
Upgrade
Debt / FCF Ratio
-0.55-0.78-0.47-0.42-0.27-
Upgrade
Quick Ratio
2.672.515.183.745.847.05
Upgrade
Current Ratio
3.122.786.434.346.267.42
Upgrade
Asset Turnover
0.100.090.010.010.010.01
Upgrade
Interest Coverage
-18.24-48.70-56.57-64.60-106.71-
Upgrade
Return on Equity (ROE)
-74.90%-110.80%-57.20%-69.30%-53.50%-115.90%
Upgrade
Return on Assets (ROA)
-33.50%-60.00%-40.40%-48.70%-42.70%-99.50%
Upgrade
Return on Capital (ROIC)
-79.65%-81.28%-52.12%-66.35%-50.09%-75.49%
Upgrade
Earnings Yield
-9.64%-320.54%-87.28%-35.99%-14.30%-17.63%
Upgrade
FCF Yield
-11.42%-158.58%-76.80%-32.46%-14.92%-7.77%
Upgrade
Buyback Yield / Dilution
-78.24%-3.24%-24.65%-6.66%-313.31%-154.25%
Upgrade
Total Shareholder Return
-78.24%-3.24%-24.65%-6.66%-313.31%-154.25%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).